The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Abstract
Background & aims Genomic studies have revealed subtypes of pancreatic ductal adenocarcinoma (PDA) based on their molecular features, but different studies have reported different classification systems. It is a challenge to obtain high-quality, freshly frozen tissue for clinical analysis and determination of PDA subtypes. We aimed to redefine subtypes of PDA using a large number of formalin-fixed and paraffin-embedded PDA samples, which are more amenable to routine clinical evaluation.Methods We collected PDA samples from 309 consecutive patients who underwent surgery from September 1996 through December 2010 at 4 academic hospitals in Europe; nontumor tissue samples were not included. Samples were formalin fixed and paraffin embedded. DNA and RNA were isolated; gene expression, targeted DNA sequencing, and immunohistochemical analyses were performed. We used independent component analysis to deconvolute normal, tumor, and microenvironment transcriptome patterns in samples. We devised classification systems from an unsupervised analysis using a consensus clustering approach of our data set after removing normal contamination components. We associated subtypes with overall survival and disease-free survival of patients using Cox proportional hazards regression with estimation of hazard ratios and 95% confidence interval. We used The Cancer Genome Consortium and International Cancer Genome Consortium PDA data sets as validation cohorts.Results We validated the previously reported basal-like and classical tumor-specific subtypes of PDAs. We identified features of the PDA, including microenvironment gene expression patterns, that allowed tumors to be categorized into 5 subtypes, called pure basal like, stroma activated, desmoplastic, pure classical, and immune classical. These PDA subtypes have features of cancer cells and immune cells that could be targeted by pharmacologic agents. Tumor subtypes were associated with patient outcomes, based on analysis of our data set and the International Cancer Genome Consortium and The Cancer Genome Consortium PDA data sets. We also observed an exocrine signal associated with acinar cell contamination (from pancreatic tissue).Conclusions We identified a classification system based on gene expression analysis of formalin-fixed PDA samples. We identified 5 PDA subtypes, based on features of cancer cells and the tumor microenvironment. This system might be used to select therapies and predict patient outcomes. We found evidence that the previously reported exocrine-like (called ADEX) tumor subtype resulted from contamination with pancreatic acinar cells. ArrayExpress accession number: E-MTAB-6134.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they suggested that their findings demonstrate that the Bailey ADEX subtype is likely contamination of pancreatic acinar cells.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [133]
In the citing paper
“Puleo et al. identified five subtypes, termed “pure basal like”, “stroma activated”, “desmoplastic”, “pure classical”, and “immune classical”133.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [133]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationBecht, É., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Sèlves, J., Laurent‐Puig, P., Sautès‐Fridman, C., Fridman, W. H., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,677
Self-citationGenomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Flagged first, then by citations
Research works printed but not linked: 3
- Nicolle, 2017, Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts, Cell Rep, 21, 2458, 10.1016/j.celrep.2017.11.003 · DOI
- Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 · DOI · Paper page
- Moffitt, 2015, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat Genet, 47, 1168, 10.1038/ng.3398 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 591
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer
Hasan, N. M., & Ahuja, N. (2019) · Cancers · doi:10.3390/cancers11121859 · Cited by 48
Klaassen, R., Steins, A., Gurney‐Champion, O. J., Bijlsma, M. F., van Tienhoven, G., Engelbrecht, M. R. W., van Eijck, C. H. J., Suker, M., Wilmink, J. W., Besselink, M. G., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12688 · Cited by 44
Abd-El-Halim, Y. M., Kaoutari, A. E., Silvy, F., Rubis, M., Bigonnet, M., Roques, J., Cros, J. F., Nicolle, R., Iovanna, J., Dusetti, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103541 · Cited by 44
Self-citationClinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 47
Storrs, E. P., Chati, P., Usmani, A., Sloan, I. H., Krasnick, B. A., Babbra, R. K., Harris, P. K. W., Sachs, C. M., Qaium, F., Chatterjee, D., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00455-z · Cited by 48
Link, J. M., Eng, J. R., Pelz, C., Hawthorne, K., Worth, P. J., Sivagnanam, S., Keith, D., Owen, S., Langer, E. M., Grossblatt-Wait, A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00881-3 · Cited by 44
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Henze, J., Tacke, F., Hardt, O., Alves, F., & Rawashdeh, W. A. (2020) · Cancers · doi:10.3390/cancers12061389 · Cited by 39
A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zhong, Z., Harmston, N., Wood, K. C., Madan, B., & Virshup, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156305 · Cited by 39
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Self-citationHigh‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1
Steins, A., van Mackelenbergh, M. G., van der Zalm, A. P., Klaassen, R., Serrels, B., Goris, S. G., Kocher, H. M., Waasdorp, C., de Jong, J. H., Tekin, C., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948780 · Cited by 38
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
Pompella, L., Tirino, G., Pappalardo, A., Caterino, M., Ventriglia, A., Nacca, V., Orditura, M., Ciardiello, F., & Vita, F. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082814 · Cited by 40
Andersen, H. B., Ialchina, R., Pedersen, S. F., & Czaplińska, D. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10004-4 · Cited by 40
Rodríguez, E., Boelaars, K., Brown, K., Madunić, K., van Ee, T., Dijk, F., Verheij, J., Li, R. J. E., Schetters, S. T. T., Meijer, L. L., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02934-0 · Cited by 38
Chen, D., Zhu, X., Tao, W., Kong, Y. Y., Huag, Y., Zhang, Y., Liu, R., Jiang, L., Tang, Y., Yu, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.001 · Cited by 38
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 41
Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors
Reyes‐Castellanos, G., Hadi, N. A., & Carrier, A. (2022) · Cells · doi:10.3390/cells11030426 · Cited by 41
Decoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 35
Tang, R., Zhang, Z., Liu, X., Liao, Y., Chen, Y., Xiao, M., Li, Y., Zhou, C., Tan, Z., Zhang, C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.019 · Cited by 36
The Tumor Microenvironment of Pancreatic Cancer
Karamitopoulou, E. (2020) · Cancers · doi:10.3390/cancers12103076 · Cited by 37
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
Malinova, A., Veghini, L., Real, F. X., & Corbo, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795251 · Cited by 39
Deep Tumor Penetrating Gold Nano‐Adjuvant for NIR‐II‐Triggered In Situ Tumor Vaccination
Chen, A., Wu, L., Luo, Y., Lu, S., Wang, Y., Zhou, Z., Zhou, D., Xie, Z., & Yue, J. (2022) · Small · doi:10.1002/smll.202200993 · Cited by 36
Swietlik, J. J., Bärthel, S., Falcomatà, C., Fink, D., Sinha, A., Cheng, J., Ebner, S., Landgraf, P., Dieterich, D. C., Daub, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38171-8 · Cited by 38
George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 35
Li, Y., Tang, S., Wang, H., Zhu, H., Lu, Y., Zhang, Y., Guo, S., He, J., Li, Y., Zhang, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.008 · Cited by 45
Felix, T. F., Lapa, R. M. L., de Carvalho, M., Bertoni, N., Tokár, T., de Oliveira, R. A., Rodrigues, M. A. M., Hasimoto, C. N., de Oliveira, W. K., Pelafsky, L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217421 · Cited by 36
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 36
Robin, F., Angenard, G., Cano, L., Courtin-Tanguy, L., Gaignard, E., Khene, Z., Bergeat, D., Clément, B., Boudjéma, K., Coulouarn, C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0863-1 · Cited by 35
Moving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34
Samain, R., Brunel, A., Douché, T., Fanjul, M., Cassant‐Sourdy, S., Rochotte, J., Cros, J. F., Neuzillet, C., Raffenne, J., Duluc, C., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.008 · Cited by 32
Self-citationHwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 35
Carpenter, E. S., Kadiyala, P., Elhossiny, A. M., Kemp, S. B., Li, J., Steele, N. G., Nicolle, R., Nwosu, Z. C., Freeman, J., Dai, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1421 · Cited by 32
Self-citationGene Targeting in Disease Networks
Weighill, D. A., Guebila, M. B., Glass, K., Platig, J., Yeh, J. J., & Quackenbush, J. F. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.649942 · Cited by 30
Suurmeijer, J. A., Soer, E. C., Dings, M. P. G., Kim, Y., Strijker, M., Bonsing, B. A., Brosens, L. A. A., Busch, O. R., Groen, J. V., Halfwerk, J. B. G., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac272 · Cited by 30
Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
Mosalem, O. M., Abdelhakeem, A. A. F., Abdel-Razeq, N. H., & Babiker, H. M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473698 · Cited by 33
Morphological Heterogeneity in Pancreatic Cancer Reflects Structural and Functional Divergence
Sántha, P., Lenggenhager, D. M., Finstadsveen, A. V., Dorg, L. T., Tøndel, K., Amrutkar, M., Gladhaug, I. P., & Verbeke, C. S. (2021) · Cancers · doi:10.3390/cancers13040895 · Cited by 33
Nishiwada, S., Cui, Y., Sho, M., Jun, E., Akahori, T., Nakamura, K., Sonohara, F., Yamada, S., Fujii, T., Han, I. W., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004993 · Cited by 30
PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
Lee, M. K. C., Grimmond, S. M., McArthur, G. A., & Sheppard, K. E. (2021) · Cancers · doi:10.3390/cancers13205136 · Cited by 30
Subtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 32
Ge, J., Ge, J., Tang, G., Xiong, D., Zhu, D., Ding, X., Zhou, X., & Sang, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05590-0 · Cited by 28
Alver, T. N., Bergholtz, H., Holm, M. B., Dorg, L. T., Skrede, M. L., Kure, E. H., & Verbeke, C. S. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100726 · Cited by 28
Dorn, Á., Glaß, M., Neu, C. T., Heydel, B., Hüttelmaier, S., Gutschner, T., & Hämmerle, M. (2020) · Cancers · doi:10.3390/cancers12051227 · Cited by 27
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28
Shichi, Y., Gomi, F., Sasaki, N., Nonaka, K., Arai, T., & Ishiwata, T. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050746 · Cited by 27
Fraunhoffer, N. A., Abuelafia, A. M., Bigonnet, M., Gayet, O., Roques, J., Nicolle, R., Lomberk, G. A., Urrutia, R. A., Dusetti, N., & Iovanna, J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00299-z · Cited by 28
Self-citationKokumai, T., Omori, Y., Ishida, M., Ohtsuka, H., Mizuma, M., Nakagawa, K., Maeda, C., Ono, Y., Mizukami, Y., Miura, S., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100102 · Cited by 28
Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021
Turpin, A., Amrani, M. E., Bachet, J., Pietrasz, D., Schwarz, L., & Hammel, P. R. (2020) · Cancers · doi:10.3390/cancers12123866 · Cited by 26
Self-citationLi, Y., Li, Y., Yu, S., Qian, L. M., Chen, K., Lai, H., Zhang, H., Li, Y., Zhang, Y., Gu, S., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.017 · Cited by 27
Immunological combination treatment holds the key to improving survival in pancreatic cancer
Sodergren, M. H., Mangal, N., Wasan, H. S., Sadanandam, A., Balachandran, V. P., Jiao, L. R., & Habib, N. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03332-5 · Cited by 25
Vallés‐Martí, A., Mantini, G., Manoukian, P., Waasdorp, C., Sarasqueta, A. F., Haas, R. R. D. G., Henneman, A. A., Piersma, S. R., Pham, T. V., Knol, J. C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112581 · Cited by 26
Li, R., He, Y., Zhang, H., Wang, J., Liu, X., Liu, H., Wu, H., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690056 · Cited by 24
van Roey, R., Brabletz, T., Stemmler, M. P., & Armstark, I. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.753456 · Cited by 26
Torre-Healy, L. A., Kawalerski, R. R., Oh, K., Chrastecka, L., Peng, X. L., Aguirre, A. J., Rashid, N. U., Yeh, J. J., & Moffitt, R. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04461-6 · Cited by 28
Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing
Xu, D., Huang, K., Chen, Y., Yang, F., Xia, C., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133166 · Cited by 25
Wei, X. C., Zhou, X., Zhao, Y., He, Y., Weng, Z., & Xu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-85680-x · Cited by 24
Li, J., Ke, J., Fang, J., & Chen, J. N. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29320 · Cited by 25
Ghareyazi, A., Mohseni, A., Dashti, H., Beheshti, A., Dehzangi, A., Rabiee, H. R., & Alinejad‐Rokny, H. (2021) · Cancers · doi:10.3390/cancers13174376 · Cited by 24
Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Heßmann, E., & Dobbelstein, M. (2021) · Cancers · doi:10.3390/cancers13246163 · Cited by 24
Kuznetsova, A. V., Попова, О. П., Panchenkov, D. N., Dyuzheva, Т. G., & Aa, I. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00886-1 · Cited by 24
Dorman, K., Zhang, D., Heinrich, K., Reeh, L., Weiss, L., Haas, M., Beyer, G., Rössler, D. C., Goni, E., Renz, B. W., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00950-0 · Cited by 25
Jiang, Z., Zheng, X., Li, M., & Liu, M. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1050-6 · Cited by 24
Matsumoto, K., Fujimori, N., Ichihara, K., Takeno, A., Murakami, M., Ohno, A., Kakehashi, S., Teramatsu, K., Ueda, K., Nakata, K., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02103-0 · Cited by 24
Reflections on depletion of tumor stroma in pancreatic cancer
Wang, W.-Q., Liu, L., Xu, J.-Z., & Yu, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.007 · Cited by 24
Medical management of pancreatic cancer: from personalization to broadening treatment strategies
Dusetti, N., Bachet, J., Chanez, B., Neuzillet, C., de Mestier, L., Williet, N., Frauhoffer, N., Nicolle, R., Boilève, A., Turpin, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102973 · Cited by 28
Self-citationKaramitopoulou, E., Andreou, A., de Mortanges, A. P., Tinguely, M., Gloor, B., & Perren, A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0144 · Cited by 24
Pietrasz, D., Sereni, E., Lancellotti, F., Pea, A., Luchini, C., Innamorati, G., Salvia, R., & Bassi, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01745-2 · Cited by 25
Masugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.323 · Cited by 23
Gao, C., Chen, J., Bai, J., Zhang, H., Tao, Y., Wu, S., Li, H., Wu, H., Shen, Q., & Yin, T. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04302-4 · Cited by 23
Potentials of “stem cell-therapy” in pancreatic cancer: An update
Chopra, N., Choudhury, S., Bhargava, S., Wajid, S., & Ganguly, N. K. (2019) · Pancreatology · doi:10.1016/j.pan.2019.09.016 · Cited by 22
Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma
Mas, L., Cros, J. F., Svrcek, M., Laethem, J. V., Emile, J., Rebours, V., Nicolle, R., & Bachet, J. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102108 · Cited by 22
Self-citationSuzuki, T., Masugi, Y., Inoue, Y., Hamada, T., Tanaka, M. H., Takamatsu, M., Arita, J., Kato, T., Kawaguchi, Y., Kunita, A., et al. (2022) · Cancer Science · doi:10.1111/cas.15398 · Cited by 21
Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib
Kim, J., Lee, T. S., Lee, M. H., Cho, I. R., Ryu, J. K., Kim, Y., Lee, S. H., & Paik, W. H. (2024) · Cancers · doi:10.3390/cancers16051056 · Cited by 22
Weng, J., Ju, F., Lyu, Z., Fan, N., Smit, D. J., Xu, W., Wu, X., Becker, P., Xu, Y., Schweiger, M. R., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03567-5 · Cited by 26
Jonckheere, N., Auwercx, J., Bachir, E. H., Coppin, L., Boukrout, N., Vincent, A., NEVE, B. P., Gautier, M., Treviño, V., & SEUNINGEN, I. V. (2020) · Cancers · doi:10.3390/cancers12113309 · Cited by 21
Raffenne, J., Martin, F. A., Nicolle, R., Konta, M., Blum, Y., Torrisani, J., Puleo, F., Bachet, J., Svrcek, M., Bardier–Dupas, A., et al. (2021) · Cancers · doi:10.3390/cancers13061234 · Cited by 21
Self-citationSong, W., He, X., Gong, P., Yang, Y. T., Huang, S., Zeng, Y., Wei, L., & Zhang, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.639246 · Cited by 21
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
Mahajan, U. M., Alnatsha, A., Li, Q., Oehrle, B., Weiß, F. U., Sendler, M., Distler, M., Uhl, W. H., Fahlbusch, T., Goni, E., et al. (2021) · Cells · doi:10.3390/cells10071821 · Cited by 21
The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer
Dreyer, S. B., Rae, S., Bisset, K., Upstill‐Goddard, R., Gemenetzis, G., Johns, A. L., Initiative, A. P. C. G., Dickson, E. J., Mittal, A., Gill, A. J., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005050 · Cited by 21
Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer
Liang, Y., Li, H., Gan, Y., & Tu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.688953 · Cited by 22
Stoof, J., Harrold, E. C., Mariottino, S., Lowery, M. A., & Walsh, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749490 · Cited by 21
Gu, X. Q., Zhu, Q., Tian, G., Song, W., Wang, T., Wang, A., Chen, X., & Qin, S. (2022) · Cancer Medicine · doi:10.1002/cam4.4683 · Cited by 21
Laise, P., Turunen, M. M., Garcia, A. C., Tomassoni, L., Maurer, H. C., Elyada, E., Schmierer, B., Worley, J., Kesner, J. S., Tan, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.27.357269 · Cited by 21
Lansbergen, M. F., Dings, M. P. G., Manoukian, P., Sarasqueta, A. F., Waasdorp, C., Hooijer, G. K. J., Verheij, J., Köster, J., Zwijnenburg, D. A., Wilmink, J. W., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.08.002 · Cited by 21
Ramesh, R. P. G., Yasmin, H., Ponnachan, P., al-Ramadi, B. K., Kishore, U., & Joseph, A. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573522 · Cited by 22
Versemann, L., Heßmann, E., & Ulisse, M. (2021) · Visceral Medicine · doi:10.1159/000519859 · Cited by 20
Tamagawa, H., Fujii, M., Togasaki, K., Seino, T., Kawasaki, S., Takano, A., Toshimitsu, K., Takahashi, S., Ohta, Y., Matano, M., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01498-5 · Cited by 22
Zhang, G., Wang, Q., Yang, M., Yao, X., Qi, X., An, Y., Dong, H., Zhang, L., Zhu, W., Li, Y., et al. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23154 · Cited by 20
Archibugi, L., Ruta, V., Panzeri, V., Redegalli, M., Testoni, S. G. G., Petrone, M. C., Rossi, G., Falconi, M., Reni, M., Doglioni, C., et al. (2020) · Cells · doi:10.3390/cells9122561 · Cited by 20
Application of single-cell sequencing technologies in pancreatic cancer
Mannarapu, M., Dariya, B., & Bandapalli, O. R. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04095-4 · Cited by 20
Schreyer, D., Neoptolemos, J. P., Barry, S. T., & Bailey, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795735 · Cited by 19
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Silwal‐Pandit, L., Stålberg, S. M., Johansson, H. J., Mermelekas, G., Lothe, I. M. B., Skrede, M. L., Dalsgaard, A. M., Nebdal, D. J. H., Helland, Å., Lingjærde, O. C., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0100 · Cited by 19
Chen, K., Liu, X., Di, L., Liu, W., Wang, F., Yang, Y., & Tian, X. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab343 · Cited by 20
Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
Iovanna, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100965 · Cited by 18
Self-citationYin, X., Kong, L., & Liu, P. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01090-w · Cited by 18
Öztürk, H., Cingoz, H., Tufan, T., Yang, J., Adair, S. J., Tummala, K. S., Kuscu, C., Kinali, M., Cömertpay, G., Nagdas, S., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.04.014 · Cited by 18
Recent advances in understanding pancreatic cancer
Stott, M. C., Oldfield, L. S., Hale, J. J., Costello, E., & Halloran, C. M. (2022) · Faculty Reviews · doi:10.12703/r/11-9 · Cited by 19
The molecular landscape of pancreatic ductal adenocarcinoma
Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.010 · Cited by 21
Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
Bryce, A. S., Dreyer, S. B., Froeling, F. E. M., & Chang, D. K.-F. (2022) · Cancers · doi:10.3390/cancers14215302 · Cited by 19
Laser Capture Microdissection: A Gear for Pancreatic Cancer Research
Rao, B. H., Souček, P., & Hlaváč, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314566 · Cited by 19
The Intricate Metabolism of Pancreatic Cancers
Camelo, F., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_5 · Cited by 19
Francescone, R., Costa, D. B. V., Franco-Barraza, J., Wagner, J., Muir, A., Lau, A. N., Gabitova, L., Pazina, T., Gupta, S., Luong, T., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/330209 · Cited by 18
Metadata
- Authors
- Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., Franchimont, D., Verset, L., Galdon, M. G., Devière, J., de Reyniès, A., Laurent-Puig, P., Van Laethem, J.-L., Bachet, J.-B., & Maréchal, R.
- Affiliations
- Université Libre de Bruxelles (BE)
- La Ligue Contre le Cancer (FR)
- Erasmus Hospital (BE)
- Hôpital Saint-Antoine (FR)
- Centre National de la Recherche Scientifique (FR)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Puleo, Francesco
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 155
- Issue
- 6
- Pages
- 1999-2013.e3
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2889433609
- Cited by
- 563
- References
- 34
- Citations by year
- 2026: 53 · 2025: 63 · 2024: 66 · 2023: 87 · 2022: 81 · 2021: 109 · 2020: 72 · 2019: 28 · 2018: 4
- FWCI
- 20.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- pancreatic ductal adenocarcinoma, tumor subtypes, tumor microenvironment, gene expression profiling, formalin-fixed paraffin-embedded tissue, desmoplasia, basal-like subtype, classical subtype, overall survival, disease-free survival, independent component analysis, consensus clustering
- MeSH terms
- Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Female, Humans, Male, Middle Aged, Pancreas, Prospective Studies, Regression Analysis, RNA, Neoplasm, Gene Expression, Proportional Hazards Models, Sequence Analysis, DNA, Disease-Free Survival, Carcinoma, Pancreatic Ductal, Pancreas, Exocrine, Tumor Microenvironment, Transcriptome, Acinar Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
